key: cord-0767381-r5mq1zcw authors: Ioannidis, John P.A. title: High-cited favorable studies for COVID-19 treatments ineffective in large trials date: 2022-04-06 journal: J Clin Epidemiol DOI: 10.1016/j.jclinepi.2022.04.001 sha: bf21c269f957dc44037bfa76bf7421c9d4fa49eb doc_id: 767381 cord_uid: r5mq1zcw Objective To evaluate for COVID-19 treatments without benefits in subsequent large RCTs how many of their most-cited clinical studies had declared favorable results. Study design Scopus searches (December 23, 2021) identified articles on lopinavir-ritonavir, hydroxycholoroquine, azithromycin, remdesivir, convalescent plasma, colchicine or interferon (index interventions) that represented clinical trials and had >150 citations. Their conclusions were correlated with study design features. The ten most recent citations for the most-cited article on each index intervention were examined on whether they were critical to the highly-cited study. Altmetric scores were also obtained. Results 40 eligible articles of clinical studies had received >150 citations. 20/40 (50%) had favorable conclusions, 4 were equivocal. Highly-cited articles with favorable conclusions were rarely RCTs (3/20) while those without favorable conclusions were mostly RCTs (15/20, p=0.0003). Only 1 RCT with favorable conclusions had >160 patients. Citation counts correlated strongly with Altmetric scores, especially news items. Only 9 (15%) of 60 recent citations to the most highly-cited studies with favorable or equivocal conclusions were critical. Conclusion Many clinical studies with favorable conclusions for largely ineffective COVID-19 treatments are uncritically heavily cited and disseminated. Early observational studies and small randomized trials may cause spurious claims of effectiveness that get perpetuated. Key findings • Many highly-cited studies with favorable conclusions for COVID-19 treatments were refuted by large trials. • The refuted highly-cited clinical studies also attracted large media and social media attention. • The refuted highly-cited trials continued to be uncritically heavily cited after their refutation. What this adds to what is known • COVID-19 clinical research can be highly prone to exaggerated claims. What is the implication/what should change now • Early observational studies and small randomized trials on COVID-19 treatments should be seen with great caution. J o u r n a l P r e -p r o o f The search for COVID-19 treatments has ushered in thousands of clinical studies, [1] [2] [3] many promises, several emergency authorizations, and some excellent successes. In particular, large adaptive randomized controlled trials (RCTs) using rapid recruitment of participants from real-world clinical practice were instrumental in documenting benefits with large-scale evidence. 4, 5 By the end of 2021 dexamethasone, tocilizumab, and monoclonal antibody combinations had shown convincing evidence that they reduce mortality in various patient groups and clinical settings. [6] [7] [8] However, the largest randomized controlled trials (RCTs) to-date, RECOVERY [9] [10] [11] [12] [13] and SOLIDARITY, 14 have also showed no benefit for several other treatments lopinavir/ritonavir, 9 hydroxycholoroquine, 10,14 azithromycin, 11 remdesivir, 14 convalescent plasma, 12 colchicine 13 and interferon. 14 All these interventions with disappointing results in the large trials had been presented as being highly promising and effective in earlier, mostly smaller studies. Each of these treatments have been debated heavily in both scientific and lay circles, often vehemently so. The unfavorable results from large trials may upset guidelines since they may even lead to reversal of emergency authorization (e.g. https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-useauthorization-chloroquine-and). tested a new treatment versus standard of care and used an index intervention as common backbone for both arms) or found that a new treatment is superior to an index intervention (thus, one cannot conclude whether the index intervention by itself is effective or not). Retracted articles and retraction notices were also excluded. Data extraction on the eligible highly-cited studies recorded the evaluated interventions, the design (randomized or not), sample size, and number of deaths. The conclusions of the authors of each eligible highly-cited study were categorized as favorable (claiming that an index treatment is beneficial or that it is safe without any mention of harm); unfavorable (claiming no J o u r n a l P r e -p r o o f benefit and/or a safety problem for an index treatment); or equivocal when there was a mixed message or potential benefit seen in some particular analysis or endpoint. Media and social media impact was assessed by the Altmetric score. The score tracks the presence of an article in media and social media, e.g. news, Twitter, blogs, Facebook, and more (https://www.altmetric.com/). Information was also obtained through Altmetric on the rank of the paper across all scientific papers tracked by Altmetric and on the number of news items and tweets mentioning each highly-cited paper. Correlations between citation counts and Altmetric score, news items, and tweets were estimated with Pearson coefficients. For each index treatment, the 10 most recent citing papers to its most highly-cited study with favorable or equivocal results were probed to assess whether the citations were critical to the highly-cited study and to identify whether the citing papers also cited the large trials with unfavorable results (RECOVERY and/or SOLIDARITY) 9-14either the final peer-reviewed publications, or the preprints, or at least some press release or other mention. 10 papers were selected as a convenience sample. Unfavorable results were announced by RECOVERY for hydroxychloroquine on June 5, 2020, for lopinavir-ritonavir on June 29, 2020, for azithromycin The Scopus search yielded 63803 results, of which 465 published items were highly-cited with >150 citations. 45/465 pertained to any of the index interventions being used in clinical studies. A retracted paper and its retraction notice, and 3 papers where the favored treatment (baricitinib, arbidol) was not an index intervention were excluded. The 40 eligible articles appear in Table 1 . 9,10,14-51 Of 40 eligible studies, 20 (50%) had favorable conclusions for the index treatments, 4 were equivocal and 16 were unfavorable. The unfavorable group included the publication of SOLIDARITY titself 14 and the publications of the hydroxychloroquine 10 and lopinavir-ritonavir 9 assessments from RECOVERY. Of 7 articles that exceeded 1,000 citations, 5 had favorable conclusions, and 2 were equivocal (one described significant benefit in modified intention-totreat analysis, and the other mentioned a non-significant trend for clinical improvement). The highly-cited articles with favorable conclusions were far less likely to be randomized controlled trials than the other highly-cited articles (3/20 versus 15/20, exact p=0.0003). The few randomized controlled trials with favorable conclusions tended to be smaller than the others (median sample size 160 versus 464). Of the 6 studies with at least 200 deaths, all three randomized trials did not reach favorable conclusions; 2/3 non-randomized studies did. All 40 highly-cited papers had very high Altmetric scores placing them at the top 5% of Only 9 (15%) of 60 recent citations to the most highly-cited studies with favorable or equivocal conclusions were critical to the highly-cited study ( Table 2 ). Citing papers uncommonly (8/60, 13%) cited the respective RECOVERY or SOLIDARITY results. Altmetric scores correlated well with citation counts. The correlation was more prominent when news items were considered, while tweets had a more modest correlation. Altmetric score analyses have shown 60 that media and social media attention may remain high even for fully retracted papers. Some caveats need to be acknowledged. The large trials may not necessarily be a gold standard. No single clinical study can claim to possess the truth. Even large trials can be biased upwards in their beneficial estimates, e.g. due to lack of blinding. However, this is less of a concern for an outcome such as mortality. The CIs of the large trials cannot exclude very small benefits on survivalor small harms. These trials have also shown no benefit on other outcomes. However, small benefits (or harms) for these outcomes can't be excluded with perfect certainty. 68 and hydroxychloroquine has shown promising results for preventive use with lower doses in a recent meta-analysis. 69 The best solution in these situations would be to consider whether there is room for conducting new large simple trials that focus on J o u r n a l P r e -p r o o f the debated settings, populations, and doses where there is continued controversy powering these trials to detect or reject the possibility of mortality benefits. The experience with SOLIDARITY and RECOVERY proves that such trials can be done quickly. The old argument that large trials take immense resources and a very long period of time to complete has been contradicted with the efficiency of the current adaptive large trial platforms. Other large trial platforms are also launched, such as the TOGETHER trial 70 and they can contribute further large-scale evidence. The procured evidence would then need to be balanced very carefully in terms of benefits and risks in different settings and populations. Acknowledging these caveats and some residual uncertainty, it is more likely that the treatments examined in the current analysis overall don't save lives. The most recent metaanalyses are also consistent with this interpretation. [71] [72] [73] [74] [75] For hydroxychloroquine, a recent collaborative meta-analysis even shows nominally statistically significantly increased mortality. 76 Prior experience from content analysis of persistent high citations of non-validated papers in other fields may offer us insights on why this situation arose also for COVID-19 treatments. One empirical evaluation 61 assessed in-depth the citation patterns of extremely highly-cited papers on the benefits of beta-carotene for cancer prevention, estrogens for Alzheimer's dementia and alpha-tocopherol for cardiovascular disease. Despite the emergence of large RCTs with unfavorable results for these interventions, the observational studies that made the original promises continued to be heavily cited long after the "negative" RCTs were published. Their citations were either ignoring the refuting RCTs (for beta-carotene), or raising numerous counterarguments against them (for estrogen and alpha-tocopherol). Similarly, in psychology, where several major claims had been found to be irreproducible in pre-registered reproducibility J o u r n a l P r e -p r o o f assessments done by many teams, frequent citation of the original claims has continued unperturbed after their non-reproduction. 77 The citing articles uncommonly take a critical stance against the original claims. 77 In other areas where evidence is heavily centered on biological considerations, citation networks citing some preferred papers may create a perpetuated distortion of what is the established knowledge. This has been seen in empirical evaluations in genetics of amygdala activation 78 and in pathology of inclusion body myositis. 79 Another empirical evaluation even found evidence of so-called "affirmative citation bias". 52 The citations to the critical articles that had thoroughly debunked prior beliefs were mostly affirmative, in favor of the original beliefs that had been debunked. The authors concluded that even criticism itself may paradoxically reinforce the establishment of debunked prior beliefs. 52 Curiously, the stronger the refutation, the stronger people stick to their beliefs, as described also by Kahnemann. 80 These observations suggest that often science is organized in cherished schools of thought that are recalcitrant to the provision and acceptance of contrarian evidence. This may have happened also in the case of the early promising COVID-19 treatments. Moreover, in COVID-19, given the vast attention devoted, the citation rates of these non-validated treatment benefits are even more extraordinary. Furthermore, the overall impact of their dissemination reverberates across wider societal circles, not just scientific groups. The advent of very large RCTs did not suffice to perturb much this intense dissemination. In conclusion, one should avoid putting much trust to highly promising results from early observational studies and small randomized trials of new or repurposed treatments. 81 For serious diseases, like COVID-19, evidence on mortality endpoints should be sought. Pilot studies should not be abandoned or dejected, and they do have some value in offering early insights. However, J o u r n a l P r e -p r o o f they should be seen with great caution and with tempered enthusiasm. Large trials with flexible designs that allow obtaining large-scale rigorous evidence in a timely manner have been a major success during the pandemic [3] [4] [5] and their use should be promoted further. J o u r n a l P r e -p r o o f The worldwide clinical trial research response to the COVID-19 pandemic -the first 100 days COVID-19: A catalyst for transforming randomized trials Lessons learned from COVID-19 trials: should we be doing trials differently? Making trials part of good clinical care: lessons from the RECOVERY trial Realising the full potential of data-enabled trials in the UK: a call for action Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Dexamethasone in Hospitalized Patients with Covid-19 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Repurposed antiviral drugs for Covid-19 -interim WHO Solidarity trial results A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Remdesivir for the treatment of COVID-19 -Final report Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Compassionate use of remdesivir for patients with severe Covid-19 Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Observational study of hydroxychloroquine in hospitalized patients with COVID-19 Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19 Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial Remdesivir for 5 or 10 days in patients with severe covid-19 Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19 No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang da xue xue bao A randomized trial of convalescent plasma in Covid-19 severe pneumonia Early high-titer plasma therapy to prevent severe Covid-19 in older adults Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: Observational comparative study using routine care data Hydroxychloroquine in nonhospitalized adults with early covid-19: A randomized trial Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection Treatment with convalescent plasma for COVID-19 patients in Wuhan Outcomes of hydroxychloroquine usage in United States Veterans hospitalized with COVID-19 Interferon-α2b treatment for COVID-19 Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea Early safety indicators of COVID-19 convalescent plasma in 5000 patients Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019 Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized J o u r n a l P r e -p r o o f with coronavirus disease 2019: The GRECCO-19 randomized clinical trial Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT Interval in patients with SARS-CoV-2 infection Affirmative citation bias in scientific myth debunking: A three-inone case study Citation bias in imaging research: are studies with higher diagnostic accuracy estimates cited more often? Citation bias: questionable research practice of scientific misconduct Citation bias: questionable research practice or scientific misconduct? Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis Don't let the truth get in the way of a good story: an illustration of citation bias in epidemiologic research How a torrent of COVID science changed research publishing -in seven charts The rapid, massive growth of COVID-19 authors in the scientific literature Media and social media attention to retracted articles according to Altmetric Persistence of contradicted claims in the literature The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the Therapeutics and COVID-19: living guideline Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 Early remdesivir to prevent progression to severe COVID-19 in outpatients Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: A network meta-analysis of randomized controlled trials Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and metaanalysis of randomized clinical trials Association of convalescent plasma treatment with clinical outcomes in COVID-19 patients: a systematic review and meta-analysis of randomized clinical trials Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials Citation patterns following a strongly contradictory replication result: Four case studies from psychology Citation distortions in the literature on the serotonin-transporter-linked polymorphic region and amygdala activation How citation distortions create unfounded authority: Analysis of a citation network Thinking, fast and slow. London: Penguin Books Why most published research findings are false